Steve Almond

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

François Raffi, Anita Rachlis, Hans‐Jürgen Stellbrink et al. · The Lancet · 2013 · 546 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

François Raffi, Hans Jaeger, Eugenia Quirós-Roldán et al. · The Lancet Infectious Diseases · 2013 · 372 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +11

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

Jan van Lunzen, Franco Maggiolo, José Ramón Arribas et al. · The Lancet Infectious Diseases · 2011 · 298 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +15

Dolutegravir in antiretroviral-naive adults with HIV-1

Hans-Jürgen Stellbrink, Jacques Reynes, Adriano Lazzarin et al. · AIDS · 2013 · 163 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials

François Raffi, Anita Rachlis, Cynthia Brinson et al. · AIDS · 2014 · 55 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17